Y.D. More Investments Ltd Buys 484 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Y.D. More Investments Ltd lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 43.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,602 shares of the biopharmaceutical company’s stock after buying an additional 484 shares during the quarter. Y.D. More Investments Ltd’s holdings in Gilead Sciences were worth $148,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth $25,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $29,000. Valued Wealth Advisors LLC boosted its stake in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. Finally, Crews Bank & Trust purchased a new position in Gilead Sciences during the fourth quarter worth about $31,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 1.7 %

Shares of NASDAQ:GILD opened at $99.65 on Thursday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock’s 50-day moving average is $92.71 and its 200 day moving average is $86.32. The company has a market cap of $124.19 billion, a PE ratio of 1,107.22, a P/E/G ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 earnings per share. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. Piper Sandler lifted their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Mizuho raised their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. BMO Capital Markets upped their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $98.39.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.